Efficacy and safety of the new intravenous immunoglobulin IGIV 10 % in adults with chronic idiopathic thrombocytopenic purpura
2006
Abstract
Background: Intravenous immunoglobulin (IGIV) 10 % is a newly developed 10 % liquid immunoglobulin preparation for intravenous use where 3 dedicated virus reduction steps have been integrated into the manufacturing process. The efficacy and safety of this product were assessed in a prospective multicenter study in chronic ITP (idiopathic thrombocytopenic purpura) patients with platelet counts of 20 * 109/l.
Conclusion: The results obtained in this study demonstrate that IGIV 10 % is effective in the treatment of adult subjects with chronic ITP and indicate a good safety profile.